Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB
[thumbnail of Supplementary Data] Other (Supplementary Data)
2MB

Item Type:Article
Title:Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
Creators Name:Basheer, F., Giotopoulos, G., Meduri, E., Yun, H., Mazan, M., Sasca, D., Gallipoli, P., Marando, L., Gozdecka, M., Asby, R., Sheppard, O., Dudek, M., Bullinger, L., Döhner, H., Dillon, R., Freeman, S., Ottmann, O., Burnett, A., Russell, N., Papaemmanuil, E., Hills, R., Campbell, P., Vassiliou, G.S.. and Huntly, B.J.P.
Abstract:Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function mutations are common in myeloid malignancies. We have examined the importance of cellular context for Ezh2 loss during the evolution of acute myeloid leukemia (AML), where we observed stage-specific and diametrically opposite functions for Ezh2 at the early and late stages of disease. During disease maintenance, WT Ezh2 exerts an oncogenic function that may be therapeutically targeted. In contrast, Ezh2 acts as a tumor suppressor during AML induction. Transcriptional analysis explains this apparent paradox, demonstrating that loss of derepresses different expression programs during disease induction and maintenance. During disease induction, loss derepresses a subset of bivalent promoters that resolve toward gene activation, inducing a feto-oncogenic program that includes genes such as , whose overexpression phenocopies loss to accelerate AML induction in mouse models. Our data highlight the importance of cellular context and disease phase for the function of Ezh2 and its potential therapeutic implications.
Keywords:Acute Myeloid Leukemia, Animal Disease Models, Bone Marrow Cells, Bone Marrow Transplantation, Cohort Studies, Disease Progression, Enhancer of Zeste Homolog 2 Protein, Gene Frequency, Genetic Transduction, Histones, Homologous Transplantation, Inbred C57BL Mice, Loss of Function Mutation, Prognosis, Survival Rate, Tumor Cell Line, Animals, Mice
Source:Journal of Experimental Medicine
ISSN:0022-1007
Publisher:Rockefeller University Press
Volume:216
Number:4
Page Range:966-981
Date:1 April 2019
Official Publication:https://doi.org/10.1084/jem.20181276
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library